|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2004-11-30
|
|
pubmed:abstractText |
Epidemiologic studies have revealed a decreased risk of colon cancer among people who have regularly taken cyclooxygenase (COX)-2 inhibitors such as aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Whereas the selective COX-2 inhibitor celecoxib and exisulind, a metabolic product of sulindac, have gained increasing attention as efficacious chemopreventive agents against colon and prostate cancer, not much is known about the underlying molecular targets and mechanisms. Moreover, the side effects of NSAIDs are a major obstacle for large-scale application to the prevention of cancer in humans; for example, in the United States in 1998, there were 16,550 deaths from NSAID-induced gastrointestinal complications. The toxicity associated with these compounds is raising concerns, and more needs to be known about their mode of action and molecular targets.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7727-37
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15570007-Adenocarcinoma,
pubmed-meshheading:15570007-Animals,
pubmed-meshheading:15570007-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:15570007-Apoptosis,
pubmed-meshheading:15570007-Blotting, Western,
pubmed-meshheading:15570007-Dietary Supplements,
pubmed-meshheading:15570007-Dinoprostone,
pubmed-meshheading:15570007-Disease Models, Animal,
pubmed-meshheading:15570007-Immunohistochemistry,
pubmed-meshheading:15570007-Male,
pubmed-meshheading:15570007-Mice,
pubmed-meshheading:15570007-Mice, Transgenic,
pubmed-meshheading:15570007-Models, Biological,
pubmed-meshheading:15570007-Phosphorylation,
pubmed-meshheading:15570007-Prostatic Intraepithelial Neoplasia,
pubmed-meshheading:15570007-Prostatic Neoplasms,
pubmed-meshheading:15570007-Pyrazoles,
pubmed-meshheading:15570007-Sulfonamides,
pubmed-meshheading:15570007-Sulindac,
pubmed-meshheading:15570007-Time Factors,
pubmed-meshheading:15570007-Transgenes
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
|
|
pubmed:affiliation |
Cancer Genomics Laboratory, Chemoprevention and Nutritional Carcinogenesis Program, and Statistics and Data Management, Institute for Cancer Prevention, Valhalla, New York 10987, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
